NCT04860518View on ClinicalTrials.gov

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
Covid19
Interventions
DRUG

IFN beta-1a

Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised

DRUG

Dexamethasone

Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised

Trial Locations (4)

37232

Vanderbilt University School of Medicine, Nashville

80045

University of Colorado Anschutz Medical Campus, Aurora

02215

Beth Israel Deaconess Medical Center, Boston

02462

Newton-Wellesley Hospital, Newton

Sponsors
All Listed Sponsors
lead

Faron Pharmaceuticals Ltd

INDUSTRY